• Polycythemia vera is a myeloproliferative neoplasm characterized by clonal hematopoiesis and an absolute increase in the red blood cell mass, with an associated leukocytosis and thrombocytosis. (targetedonc.com)
  • The effectiveness of interferon (IFN) in patients with myeloproliferative neoplasms (MPNs) including polycythemia vera (PV) has been reported for more than three decades. (bvsalud.org)
  • Melanonychia develops in about 4.3% of the patients receiving hydroxyurea therapy. (bmj.com)
  • High-risk patients should be considered for treatment with cytoreductive therapies, of which hydroxyurea is considered first line. (targetedonc.com)
  • For patients with hydroxyurea-resistant disease or those who are unable to tolerate this chemotherapy, the selective JAK1/2 inhibitor ruxolitinib (Jakafi) is an approved second-line option. (targetedonc.com)
  • JAK2 inhibition for PV remains a viable option for a subset of patients that fail hydroxyurea and are particularly in need of symptomatic control. (targetedonc.com)
  • Guidelines in Western countries recommend IFN as the first choice for cytoreduction alongside hydroxyurea, particularly for young and pregnant patients. (bvsalud.org)
  • Since 3 years, she received treatment for polycythaemia vera with hydroxyurea in varying doses ranging from 500 to 1500 mg daily. (bmj.com)
  • Multiple longitudinal brown bands on the toenails of digiti I-III of the right foot during treatment with hydroxyurea (A) and 6 weeks after discontinuation of hydroxyurea (B). (bmj.com)
  • Ruxolitinib was approved by the FDA for the treatment of hydroxyurea-refractory or intolerant PV based on the results of the randomized, phase III RESPONSE trial. (targetedonc.com)
  • 1 The onset of the melanonychia varies from 4 weeks to 5 years after initiation of the hydroxyurea. (bmj.com)
  • Myelofibrosis can also result from a worsening of other bone marrow diseases, such as polycythemia vera and essential thrombocythemia. (radiationoncologyassociates.co)
  • Slightly different criteria are used to diagnose myelofibrosis that develops after polycythemia vera or essential thrombocythemia 3 . (radiationoncologyassociates.co)
  • Known as a JAK inhibitor, it is a targeted therapy that is intended for patients with intermediate- or high-risk myelofibrosis (including myelofibrosis that develops after polycythemia vera or essential thrombocythemia). (radiationoncologyassociates.co)
  • Myeloproliferative disorders are considered clonal hematopoietic stem cell disorders characterized by excessive proliferation and production of one or more of the myeloid cells and are classified according to the predominant cells, such as chronic myelogenous leukemia (CML), chronic eosinophilic leukemia (CEL), polycythemia vera (PV), essential thrombocythemia (ET), and chronic idiopathic myelofibrosis (CIMF). (nih.gov)